Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNA C - EuroVacc

Drug Profile

DNA C - EuroVacc

Alternative Names: DNA-C; DNA-HIV-C; DNA-HIV-PT123 vaccine; HIV clade C DNA vaccine; HIV DNA vaccine - EuroVacc

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EuroVacc Foundation; GENEART; University of Regensburg
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; HIV Vaccine Trials Network; International AIDS Vaccine Initiative; IPPOX Foundation; Medical Research Council; MRC/UVRI Uganda Research Unit on AIDS; National Institute of Allergy and Infectious Diseases; Novartis
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 03 Sep 2019 MRC/UVRI Uganda Research Unit on Aids plans a phase II trial for HIV-1 infections (Prevention; Combination therapy) in Uganda in January 2020 (NCT04066881)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Switzerland (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Uganda (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top